Aurobindo Pharma announced its Unaudited Financial Results for Q3FY26, showcasing robust top-line growth. Revenue from operations reached ₹8,646 Cr, marking an 8.4% YoY increase, primarily driven by strong performance in Europe. The company reported an EBITDA of ₹1,773 Cr with a margin of 20.5%. Net Profit attributable to owners grew by 7.6% YoY to ₹910 Cr. The company also highlighted significant progress in its CuraTeQ biosimilars pipeline.
Q3FY26 Financial Performance Highlights
Aurobindo Pharma has posted strong financial results for the third quarter of FY26 (ended December 31, 2025). Revenue from operations stood at ₹8,646 Cr, reflecting an 8.4% Year-over-Year (YoY) growth. This revenue growth was propelled by strong European performance, which offset lower transient product sales in the US.
Key Financial Metrics (Q3FY26 vs. Q3FY25)
- Revenue: ₹8,646 Cr (up 8.4% YoY)
- EBITDA: ₹1,773 Cr (up 9.0% YoY) with a margin of 20.5%
- Net Profit (attributable to owners): ₹910 Cr (up 7.6% YoY)
Quarter-on-quarter (QoQ), revenue grew by 4.3%, and the EBITDA margin saw an increase of 26 bps to reach 20.5%.
Business Segment Breakdown
The consolidated performance shows growth primarily led by Formulations, while the API segment experienced a marginal decline.
Formulations Performance
- Total Formulations Revenue: Increased 10.4% YoY to ₹7,683 Cr.
- USA Revenue (Excluding Puerto Rico): Increased 1% QoQ to US$ 420 Mn, stabilizing the base business. The US accounted for 43.2% of consolidated revenue.
- Europe Revenue: Showed significant growth of 27.4% YoY (in INR terms) reaching ₹2,703 Cr (11% YoY growth in EUR Mn).
- ARV Revenue: Grew 22.4% YoY to ₹376 Mn (US$ Mn).
API Performance
- Total API Revenue: Declined by 4.3% YoY to ₹963 Cr, impacted by market conditions.
Operational and Strategic Highlights
CuraTeQ Biologics Update
The company emphasized sustained momentum in its biosimilars division, CuraTeQ. Key updates include:
- Approvals in Regulated Markets (RMs): Approvals secured in the EEA, UK, and Canada for products like Zefylti, Dyrupeg, Dazublys, and Bevqolva.
- Product Pipeline: Two programs, including a biosimilar to Avastin (BP01) and a biosimilar to Lucentis (BP05), are in Phase 3 clinical studies.
- Upcoming Filings in 2026: Plans to file BP16 (denosumab biosimilar) and BP11 (omalizumab biosimilar) in 2026 for EU MAA and US BLA submissions.
- Market Opportunity: The total addressable market for biosimilars in the next decade is estimated at over $50 Bn USD.
US Market and Filings
In the US market, the company launched 9 products during the quarter and received approval for 7 ANDAs.
As of December 31, 2025, the company has a total of 879 ANDA filings in the US, with 719 having final approval, covering an addressable market size of approximately $197.2 Bn USD.
Capital Expenditure and Cash Flow
Net Capex for the quarter was US$ 79 million, primarily for capability enhancements. Free Cashflows generated totaled $118 million. The Net Cash position (including investments) after the Khandelwal Labs acquisition stood strong at approximately US$ 251 million as on December 31, 2025.
Outlook and Growth Priorities
Key future priorities include securing launch momentum in Europe (e.g., Bevqolva in the UK), prioritizing launches across EEA markets, and expanding into growth markets like LATAM. The company is also planning the entry of the extended trastuzumab portfolio (600 mg subcutaneous) into clinical studies in CY2026.
Source: BSE
